Integral Health Asset Management’s Agios Pharmaceuticals AGIO Stock Holding History

Integral Health Asset Management’s Portfolio AGIO Stock Details AGIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-213,000	Closed	-$4.89M	–	77
2023 Q1	$4.89M	Buy	+213,000	New	+$5.66M	0.99%	41
2022 Q4	–	Sell	-100,000	Closed	-$2.83M	–	62
2022 Q3	$2.83M	Buy	+100,000	New	+$2.68M	0.55%	57
2021 Q4	–	Sell	-20,000	Closed	-$923K	–	72
2021 Q3	$923K	Sell	20,000 -10,000	-33%	-$483K	0.27%	66
2021 Q2	$1.65M	Sell	30,000 -13,000	-30%	-$727K	0.46%	56
2021 Q1	$2.22M	Sell	43,000 -32,000	-43%	-$1.58M	0.63%	50
2020 Q4	$3.25M	Sell	75,000 -45,000	-38%	-$1.78M	0.97%	38
2020 Q3	$4.2M	Sell	120,000 -30,000	-20%	-$1.31M	1.28%	27
2020 Q2	$8.02M	Hold	150,000	–	–	2.4%	13
2020 Q1	$5.32M	Sell	150,000 -40,000	-21%	-$1.85M	2.34%	17
2019 Q4	$9.07M	Buy	+190,000	New	+$7.18M	3.53%	8

Other funds holding AGIO

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Integral Health Asset Management's AGIO Position: Q2 2023 in Review

Integral Health Asset Management sold out of Agios Pharmaceuticals (AGIO) in Q2 2023, closing a stake of 213,000 shares — an estimated $4.89M sold.

Integral Health Asset Management first reported a position in AGIO in Q4 2019 and held it in 10 quarters. The position peaked at $9.07M in Q4 2019. 153 funds tracked by Wall St. Rank hold AGIO as of Q2 2023.

Integral Health Asset Management reported no remaining Agios Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
Integral Health Asset Management sold 213,000 Agios Pharmaceuticals shares in Q2 2023, an estimated $4.89M.
Integral Health Asset Management first reported a position in Agios Pharmaceuticals in Q4 2019 and held it in 10 quarters.
Integral Health Asset Management's Agios Pharmaceuticals position peaked at $9.07M in Q4 2019.
153 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q2 2023.

Based on Integral Health Asset Management's 13F filing for Q2 2023, filed 11 Aug 2023.